6.26
-1.57%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jinling Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 000919.SZ. It has been listed since 18 November 1999. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.20bn and net income of CN¥53.9m. At that date it held total assets of CN¥6.01bn and shareholders' equity of CN¥3.78bn.
Jinling Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Nanjing, Jiangsu. The Company’s main products include Mailuoning injections, ferrous succinate tablets and Lentinan injection, among others. The firm is also involved in the provision of medical services and the sale of medical instrument. The firm distributes its products in domestic market, with North China as its main market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Nov 1999
- Employees
- 4,880
- Website
- jlyy1999.com ↗
Leadership
Pay as last reported
- Mr. Sheng ChenChairman of the Board, since 2019CN¥739,800
- Mr. Hai ChenPresident, Director, since 2022
- Mr. Yang WangFinance Director, Chief Accounting Officer, Vice President, Secretary of the Board, Director, since 2017CN¥736,600
- Mr. Jian WangExecutive Vice President, Director, since 2019CN¥741,700
- Mr. Jian LiVice President, Chief Quality OfficerCN¥728,300
- Mr. Yuanxin FanAssistant to President
- Ms. Mingyi JiaChief EngineerCN¥732,100
- Mr. Quan LiAssistant to the President, Chief EconomistCN¥665,700
- Ms. Xin LiuAssistant to President
- Mr. Zhenxin XiAssistant to the President
- Mr. Xinning ZhuAssistant to the PresidentCN¥485,400
- Mr. Xiaoqiang CaoDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Jinling Pharmaceutical Co Ltd manufactures Mailuoning injections, a key product in its pharmaceutical portfolio.
- The company operates in the Health Care sector with a strong presence in the Pharmaceuticals industry.
- Jinling Pharmaceutical has a domestic market focus, primarily serving North China as its main market segment.
Weaknesses
- Jinling Pharmaceutical's product line is limited to Mailuoning injections, ferrous succinate tablets, and Lentinan injection as main products.
- The company's operations are confined to the domestic market, with no mention of international expansion.
- Jinling Pharmaceutical has only one headquarters city, Nanjing, which may limit its geographic reach.
Opportunities
- Jinling Pharmaceutical can expand its product offerings beyond Mailuoning injections, ferrous succinate tablets, and Lentinan injection.
- The company has potential to enter international markets, leveraging its existing domestic success.
- Jinling Pharmaceutical could grow its medical services and medical instrument sales segments.
Threats
- Jinling Pharmaceutical faces competition in the domestic market, particularly in North China.
- The company's reliance on a single headquarters city, Nanjing, may expose it to regional economic risks.
- Jinling Pharmaceutical's limited product diversity could make it vulnerable to market shifts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.